501 CANAL BLVD., RICHMOND, CA
In Re.
Sangamo Therapeutics Delisted from Nasdaq Following SEC Filing
Investor Presentation
Sangamo Therapeutics Files for Chapter 11 Bankruptcy Protection
Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones
Material disclosure
News, Letter Re Change in Certifying Accountant
Notice of Late Filing for Quarterly Report
Q1
Amended Annual Report
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Notification Filed by a National Security Exchange
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Free Writing Prospectus
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement